GENFIT Announces Details for June 2025 Shareholders’ Meeting

Genfit SA ( (GNFT) ) has shared an announcement.

On May 7, 2025, GENFIT announced the details of its upcoming Combined Shareholders’ Meeting scheduled for June 17, 2025, in Lille, France. The meeting will be available for live viewing and recorded for later access on the company’s website. Shareholders can vote online via the VOTACCESS platform, with a tutorial provided for ease of use. This meeting is significant as it reflects GENFIT’s commitment to transparency and shareholder engagement, potentially impacting its market positioning and stakeholder relations.

Spark’s Take on GNFT Stock

According to Spark, TipRanks’ AI Analyst, GNFT is a Neutral.

Genfit SA’s overall stock score is driven by its strong financial recovery and positive technical indicators, indicating a favorable trajectory. However, the high P/E ratio suggests an overvaluation risk, which could impact investor sentiment if growth expectations are not met. The absence of earnings call insights limits the assessment of future guidance and sentiment.

To see Spark’s full report on GNFT stock, click here.

More about Genfit SA

GENFIT is a late-stage biopharmaceutical company focused on developing treatments for rare and life-threatening liver diseases. The company has a strong history in liver disease research and development, with a diverse portfolio of programs targeting conditions such as Acute-on-Chronic Liver Failure, cholangiocarcinoma, urea cycle disorder, and organic acidemia. GENFIT is also involved in diagnostics, with products like NIS2+® for Metabolic dysfunction-associated steatohepatitis. Headquartered in Lille, France, GENFIT is listed on Nasdaq and Euronext.

Average Trading Volume: 12,826

Technical Sentiment Signal: Buy

Current Market Cap: $233.1M

See more data about GNFT stock on TipRanks’ Stock Analysis page.